CXCR6/CXCL16 has also been described as an oncogenic axis in a variety of solid cancers, such as papillary thyroid carcinoma, gastric, prostate, and breast cancer, through positive regulation of survival pathways such as ERK [21–25]. Here, CXCL16 is linked to thyroid gland papillary carcinoma.